Patriquin, Christopher J.
Bogdanovic, Andrija
Griffin, Morag
Kelly, Richard J.
Maciejewski, Jaroslaw P.
Mulherin, Brian
Peffault de Latour, Régis
Röth, Alexander
Selvaratnam, Veena
Szer, Jeffrey
Al-Adhami, Mohammed
Horneff, Regina
Tan, Lisa
Yeh, Michael
Panse, Jens
Funding for this research was provided by:
Apellis Pharmaceuticals
Swedish Orphan Biovitrum
Article History
Received: 7 December 2023
Accepted: 19 February 2024
First Online: 4 April 2024
Declarations
:
: Michael Yeh is an employee of Apellis and holds stock options. Mohammed Al-Adhami was an employee of Apellis at the time of study completion. Christopher J. Patriquin reports relationships with Alexion, Apellis, Regeneron, Takeda, BioCryst, Swedish Orphan Biovitrum AB, Amgen, and Novartis. Andrija Bogdanovic reports relationships with Novartis, Takeda, Pfizer, and Apellis. Morag Griffin reports consultancy at Biocryst and Regeneron; honoraria from Alexion and Swedish Orphan Biovitrum AB; advisory board member at Novartis, Biocryst, Alexion, Amgen, and Swedish Orphan Biovitrum AB; and educational work sponsored by Apellis with unrestricted grant paid to Medscape. Richard J. Kelly has received research funding from Novartis, reports consultancy for Swedish Orphan Biovitrum AB, sat on advisory boards for Alexion, AbbVie, Amgen, Jazz, Novartis, and Swedish Orphan Biovitrum AB, and received lecture fees from Alexion, Astellas, Amgen, Biologix, Jazz, and Swedish Orphan Biovitrum AB. Jaroslaw P. Maciejewski has nothing to disclose. Brian Mulherin has nothing to disclose. Régis Peffault de Latour has nothing to disclose. Alexander Röth reports personal fees from Alexion, Apellis, Kira, Novartis, Roche, Swedish Orphan Biovitrum AB, Sanofi, Bioverativ, and Grifols; and grants from Roche. Veena Selvaratnam has received consultant fees from Apellis. Jeffrey Szer reports consultancy at Novartis, Alexion, and Apellis; honoraria from Takeda, Pfizer, Novartis, Prevail Therapeutics, and Alexion; speakers’ bureau at Takeda, Pfizer, Novartis, and Alexion; and membership on an entity’s board of directors or advisory committees at Prevail Therapeutics and Alexion. Regina Horneff is an employee of Swedish Orphan Biovitrum AB. Lisa Tan is a consultant for Swedish Orphan Biovitrum AB. Jens Panse reports consultancy and honoraria at Blueprint Medicines, Amgen, F. Hoffmann-La Roche, MSD, Bristol Myers Squibb, Alexion, AstraZeneca, Novartis, Pfizer, Gilead, Boehringer Ingelheim, Swedish Orphan Biovitrum AB, and Apellis; and honoraria from Swiss Biopharma.
: Parent study and 307-OLE protocols were designed and monitored in accordance with the ethical principles of Good Clinical Practice and the Declaration of Helsinki [–]. These protocols were approved by an institutional review board or independent ethics committee at each center. Each patient provided written informed consent before undergoing study-related procedures.